

Steps taken after granting the Marketing Authorisation

- Following the first annual re-assessment the CVMP concluded on 17 June 2009 that, in relation to the specific obligations, the evidence continued to support a favourable benefit/risk profile for Nobilis Influenza H5N6. However, in view of the need for further data, full approval will remain conditional on the fulfilment of these outstanding specific obligations as outlined in Annex II of the Opinion. Amendments have been incorporated into the relevant sections of the Commission Decision and of this EPAR.

Medicinal product no longer authorised